[{"address1": "Building 1", "address2": "8th floor No. 6 Taihe Road Beijing Economic and Technological Development Zon", "city": "Beijing", "zip": "100176", "country": "China", "website": "https://www.pharmaron.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vitro biology, DMPK, in vivo pharmacology, and compound management services; chemistry, manufacturing, and controls services. It also provides clinical development services, including integrated radio labelled science, clinical development, and clinical trial recruitment services; safety assessment, integrated drug discovery, and bioanalysis services; and biologics and cell and gene therapy services, comprising biologics laboratory, biologics CDMO, cell and gene therapy laboratory, and gene therapy CDMO services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.", "fullTimeEmployees": 20342, "companyOfficers": [{"maxAge": 1, "name": "Dr. Boliang  Lou Ph.D.", "age": 60, "title": "Chairman & CEO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 309891, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Xiaoqiang  Lou EMBA", "age": 55, "title": "Co-Founder, President, COO & Executive Director", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 267786, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Bei  Zheng M.A, M.A.", "age": 56, "title": "Executive VP & Executive Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 224558, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shing Chung  Li C.F.A., CPA", "age": 45, "title": "CFO & Secretary of the Board", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hua  Yang Ph.D.", "age": 61, "title": "Chief Scientific Officer & Deputy Manager", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Connie  Sun Ph.D.", "title": "Senior VP & Global Head of Business Development of Small Molecules", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Celina  Zhong M.B.A., MBA", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Katherine  Lee M.B.A., MBA", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen  Lewinton", "title": "Senior Vice President of UK Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jingqi  Huang", "title": "Senior Vice President of In Vivo Pharmacology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 4, "compensationRisk": 2, "shareHolderRightsRisk": 4, "overallRisk": 2, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "open": 1.93, "dayLow": 1.93, "dayHigh": 1.93, "regularMarketOpen": 1.93, "regularMarketDayLow": 1.93, "regularMarketDayHigh": 1.93, "dividendRate": 0.03, "dividendYield": 0.0146, "exDividendDate": 1719446400, "payoutRatio": 0.35900003, "beta": 0.7, "trailingPE": 16.083334, "volume": 100, "regularMarketVolume": 100, "bid": 0.5978, "ask": 1.73, "marketCap": 4696790016, "fiftyTwoWeekLow": 1.93, "fiftyTwoWeekHigh": 2.25, "priceToSalesTrailing12Months": 0.4083334, "fiftyDayAverage": 1.93, "twoHundredDayAverage": 2.1204, "trailingAnnualDividendRate": 0.2, "trailingAnnualDividendYield": "Infinity", "currency": "USD", "enterpriseValue": 7064222720, "profitMargins": 0.16765, "floatShares": 1128129668, "sharesOutstanding": 301536992, "heldPercentInsiders": 0.03097, "heldPercentInstitutions": 0.28099, "bookValue": 7.309, "priceToBook": 0.264058, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 1.016, "netIncomeToCommon": 1928406016, "trailingEps": 0.12, "enterpriseToRevenue": 0.614, "enterpriseToEbitda": 3.167, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "PHBBF", "underlyingSymbol": "PHBBF", "shortName": "PHARMARON BEIJING CO LTD", "longName": "Pharmaron Beijing Co., Ltd.", "firstTradeDateEpochUtc": 1695821400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "637963d9-c722-3b11-9784-17ff8dbc6f3b", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.93, "recommendationKey": "none", "totalCash": 2819105536, "totalCashPerShare": 1.586, "ebitda": 2230889472, "totalDebt": 5793425920, "quickRatio": 1.416, "currentRatio": 1.808, "totalRevenue": 11502341120, "debtToEquity": 42.376, "revenuePerShare": 6.484, "returnOnAssets": 0.03976, "returnOnEquity": 0.14479, "freeCashflow": -940637120, "operatingCashflow": 2573069312, "earningsGrowth": 1.015, "revenueGrowth": 0.006, "grossMargins": 0.34267, "ebitdaMargins": 0.19395, "operatingMargins": 0.124910004, "financialCurrency": "CNY", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]